Arcus Biosciences target price raised to $41 from $40
RCUS•Truist Securities raised its target price for Arcus Biosciences to $41 from $40.
Related News
INmune Bio targets UK Ebstrocel approval in mid-2027
INMB•
Cencora raises fiscal 2026 adjusted diluted EPS outlook to at least $17.90
COR•
Valeo teams up with NVIDIA to develop autonomous driving computing platforms
NVDA•
Bolt, Nvidia to kickstart driverless taxi programme in Madrid during 2027
NVDA•
Supermicro partners with Nokia to deploy AI-RAN networks using Nvidia technology
SMCI•